Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
The primary objectives of this study are to evaluate the safety and efficacy of filgotinib
during induction and maintenance treatment of moderately to severely active Crohn's disease
(CD) in participants who are biologic-naive and biologic-experienced.
Participants who complete the study, or do not meet protocol response or remission criteria
at Week 10 will have the option to enter a separate long-term extension (LTE) study (Gilead
Study GS-US-419-3896).
Phase
Phase 3
Funding Agency/Sponsor
Industry
Disease
Gastrointestinal, Stomach, Esophageal
Enrollment Eligibility
Key Inclusion Criteria:
- Males or non-pregnant, non-lactating females, ages 18 to 75 years, inclusive based on
the date of the screening visit
- Documented diagnosis of CD with a minimum disease duration of 3 months with
involvement of the ileum and/or colon at a minimum, as determined by histopathology
and endoscopic assessment
- Moderately to severely active CD
- Cohort A (Biologic Naïve): Previously demonstrated an inadequate clinical response,
loss of response to, or intolerance to at least 1 of the following agents (depending
on current country treatment recommendations/guidelines): corticosteroids and
immunomodulators
- Cohort A (Biologic Experienced): Previously demonstrated an inadequate clinical
response, loss of response to, or intolerance to at least 1 of the following agents
(depending on current country treatment recommendations/guidelines) or discontinuation
of use of at least one of the following agents for reasons other than inadequate
clinical response, loss of response or intolerance: tumor necrosis factor alpha (TNFa)
antagonists, vedolizumab, and ustekinumab
- Cohort B (Biologic Experienced): Previously demonstrated an inadequate clinical
response, loss of response to, or intolerance to at least 1 of the following agents
(depending on current country treatment recommendations/guidelines): TNFa antagonists,
vedolizumab, and ustekinumab
Key Exclusion Criteria:
- Current complications of CD such as symptomatic strictures, severe rectal/anal
stenosis, fistulae other than perianal fistulae, short bowel syndrome, etc.
- Presence of ulcerative colitis, indeterminate colitis, ischemic colitis, fulminant
colitis, or toxic mega-colon
- Active tuberculosis (TB) or history of latent TB that has not been treated
- Use of any prohibited concomitant medications as described in the study protocol
NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.